ATAI Life Sciences N.V. Common Shares Stock Prediction
AI-powered sentiment analysis and prediction trends for ATAI, updated each market day.
ATAI AI Sentiment
AI sees no strong directional signal for ATAI Life Sciences N.V. Common Shares stock over the next 10 market days.
Prediction date: April 30, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About ATAI Life Sciences N.V. Common Shares
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
Sector
Exchange
Market Cap
$1,750,193,593
Cap Tier
Employees
99
Headquarters
NEW YORK, NY
Listed Since
June 18, 2021
Website
ATAI Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ATAI Volatility
ATAI Life Sciences N.V. Common Shares has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
